Literature DB >> 9302735

Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus.

S Yang1, M W Carroll, A P Torres-Duarte, B Moss, E A Davidson.   

Abstract

Genes encoding four different C-terminal fragments of a Plasmodium falciparum merozoite surface antigen were generated: MSA1C-(Si,A), containing signal and anchor regions of MSA1; MSA1C-(Si,nA), containing the signal but not the anchor; MSA1C-(nSi,A), containing the anchor but not the signal, and MSA1C-(nSi,nA) containing neither the signal nor the anchor region. Each gene was inserted into the thymidine kinase region of vaccinia virus, under the control of a synthetic strong early/ late promoter. When the plasmodial genes were expressed in cells infected by the recombinant vaccinia virus, the two proteins containing the signal region were transported to the surface of infected cells. Infection of mice and rabbits with the latter recombinant viruses stimulated C-terminal-specific antibody levels that were 10-80-fold higher than those induced by the two recombinant viruses without the signal region. The combination of the signal and anchor regions with the C-terminal MSA1 protein also generated the most effective neutralization in a P. falciparum invasion assay.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9302735     DOI: 10.1016/s0264-410x(97)00039-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

Review 1.  Enhancing poxvirus vectors vaccine immunogenicity.

Authors:  Juan García-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.

Authors:  Eva Calvo-Pinilla; Simon Gubbins; Peter Mertens; Javier Ortego; Javier Castillo-Olivares
Journal:  Antiviral Res       Date:  2018-04-18       Impact factor: 5.970

Review 3.  Utilizing poxviral vectored vaccines for antibody induction-progress and prospects.

Authors:  Simon J Draper; Matthew G Cottingham; Sarah C Gilbert
Journal:  Vaccine       Date:  2013-06-05       Impact factor: 3.641

4.  One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection.

Authors:  Ruikang Liu; Jeffrey L Americo; Catherine A Cotter; Patricia L Earl; Noam Erez; Chen Peng; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-23       Impact factor: 11.205

5.  MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease.

Authors:  Ruikang Liu; Jeffrey L Americo; Catherine A Cotter; Patricia L Earl; Noam Erez; Chen Peng; Bernard Moss
Journal:  bioRxiv       Date:  2021-01-01

6.  Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate.

Authors:  Shan Mei; Zhangling Fan; Xiaoman Liu; Fei Zhao; Yu Huang; Liang Wei; Yamei Hu; Yu Xie; Liming Wang; Bin Ai; Chen Liang; Fengwen Xu; Fei Guo
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.